Did not receive verification mail? Please confirm whether the mailbox is correct or not Re send mail
IPR Daily
- 2023-12-07 18:36:46
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, announced an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc. (Sun Pharma).
Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AGA). The agreement includes an upfront payment of $15 million, regulatory and commercial milestones, and royalties. Aclaris exclusively licenses the patents from a third party, and has separate contractual obligations under which it owes a portion of the consideration received from Sun Pharma.
“We are pleased to announce this patent license agreement with Sun Pharma, which represents our second out-license for this patent portfolio,” stated James Loerop, Chief Business Officer of Aclaris.
Source: yahoo.com - Robert A. Doody Jr.
Editor: IPR Daily-Horace
- I also said the two sentence
- Also you can enter 140words
Chang Tsi & Partners Assists High Performance Industries, Inc. (U.S.) in Successfully Combating Intellectual Property Infringement on Cross-Border E-commerce Platform
The Launch Ceremony of the 3rd Foshan High - value Patent Achievement Transfer and Transformation Competition Held
The Rise of FRAND Interim Licenses
The Supreme People's Court and the Beijing Intellectual Property Court Deliver Dual Verdicts, Finalizing Copyright Ownership of "Ultraman" in China!
